Travere Therapeutics Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study

Reuters11-07

Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study

Travere Therapeutics Inc. has announced new data from the Phase 3 DUPLEX Study evaluating FILSPARI® (sparsentan) in patients with focal segmental glomerulosclerosis $(FSGS)$. The results, which were presented as a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, demonstrate that FILSPARI-treated patients were significantly more likely to achieve proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan. Achieving this threshold was associated with a reduced risk of kidney failure. Additional analysis using data from the UK National Registry of Rare Kidney Disease (RaDaR) showed that reductions in urine protein-to-creatinine ratio (UPCR) correlated with decreased five-year risk of kidney failure. The findings support the conclusions of the PARASOL Project, which identified UPCR below 0.7 g/g as a meaningful target in FSGS management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106843166) on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581090614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 00:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581090614","market":"nz","top_or_hot":-1,"title":"Travere Therapeutics Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has announced new data from the Phase 3 DUPLEX Study evaluating FILSPARI® (sparsentan) in patients with focal segmental glomerulosclerosis <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a>. The results, which were presented as a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, demonstrate that FILSPARI-treated patients were significantly more likely to achieve proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan. Achieving this threshold was associated with a reduced risk of kidney failure. Additional analysis using data from the UK National Registry of Rare Kidney Disease (RaDaR) showed that reductions in urine protein-to-creatinine ratio (UPCR) correlated with decreased five-year risk of kidney failure. The findings support the conclusions of the PARASOL Project, which identified UPCR below 0.7 g/g as a meaningful target in FSGS management.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106843166) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 00:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has announced new data from the Phase 3 DUPLEX Study evaluating FILSPARI® (sparsentan) in patients with focal segmental glomerulosclerosis <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a>. The results, which were presented as a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, demonstrate that FILSPARI-treated patients were significantly more likely to achieve proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan. Achieving this threshold was associated with a reduced risk of kidney failure. Additional analysis using data from the UK National Registry of Rare Kidney Disease (RaDaR) showed that reductions in urine protein-to-creatinine ratio (UPCR) correlated with decreased five-year risk of kidney failure. The findings support the conclusions of the PARASOL Project, which identified UPCR below 0.7 g/g as a meaningful target in FSGS management.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106843166) on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL29X9jj:1","article_id":"2581090614","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581090614","pubTimestamp":1762444836,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Travere Therapeutics Inc. has announced new data from the Phase 3 DUPLEX Study evaluating FILSPARI  in patients with focal segmental glomerulosclerosis . The results, which were presented as a late-breaking poster at the American Society of Nephrology  Kidney Week 2025 in Houston, demonstrate that FILSPARI-treated patients were significantly more likely to achieve proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan. Achieving this threshold was associated with a reduced risk of kidney failure. Additional analysis using data from the UK National Registry of Rare Kidney Disease  showed that reductions in urine protein-to-creatinine ratio  correlated with decreased five-year risk of kidney failure. The findings support the conclusions of the PARASOL Project, which identified UPCR below 0.7 g/g as a meaningful target in FSGS management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Travere Therapeutics报告FSGS研究中FILSPARI显著降低蛋白尿和肾衰竭风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"Travere Therapeutics Reports FILSPARI Significantly Lowers Proteinuria and Kidney Failure Risk in FSGS Study\n    \n\n        Travere Therapeutics Inc. has announced new data from the Phase 3 DUPLEX Study evaluating FILSPARI® (sparsentan) in patients with focal segmental glomerulosclerosis $(FSGS)$. The results, which were presented as a late-breaking poster at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, demonstrate that FILSPARI-treated patients were significantly more likely to achieve proteinuria levels below 0.7 g/g compared to those receiving the maximum labeled dose of irbesartan. Achieving this threshold was associated with a reduced risk of kidney failure. Additional analysis using data from the UK National Registry of Rare Kidney Disease (RaDaR) showed that reductions in urine protein-to-creatinine ratio (UPCR) correlated with decreased five-year risk of kidney failure. The findings support the conclusions of the PARASOL Project, which identified UPCR below 0.7 g/g as a meaningful target in FSGS management.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251106843166) on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581090614","isCrawlerRequest":true}